Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome

Drugs

Volumn 77, Issue 9, 2017, Pages 1009-1016

  Keating, Gillian M ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ELUXADOLINE; DELTA OPIATE RECEPTOR; GASTROINTESTINAL AGENT; IMIDAZOLE DERIVATIVE; PHENYLALANINE;

ABDOMINAL PAIN; ARTICLE; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; IRRITABLE COLON; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; PANCREATITIS; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); UPPER RESPIRATORY TRACT INFECTION; VATER PAPILLA STENOSIS; ADULT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DOUBLE BLIND PROCEDURE; FEMALE; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; QUALITY OF LIFE;

ADULT; CONSTIPATION; DIARRHEA; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IMIDAZOLES; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PHENYLALANINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, OPIOID, DELTA;

EID: 85019073956     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-017-0756-7     Document Type: Article

References (28)

1. Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology. 2016;150:1393–407.
2. Lacy BE. Emerging treatments in neurogastroenterology: eluxadoline—a new therapeutic option for diarrhea-predominant IBS. Neurogastroenterol Motil. 2016;28(1):26–35.
3. Breslin HJ, Diamond CJ, Kavash RW, et al. Identification of a dual δ OR antagonist/µ OR agonist as a potential therapeutic for diarrhea-predominant irritable bowel syndrome (IBS-d). Bioorg Med Chem Lett. 2012;22(14):4869–72.
4. European Medicines Agency. Truberzi (eluxadoline): EU summary of product characteristics. 2016. http://www.ema.europa.eu/. Accessed 1 Feb 2017.
5. Wade PR, Palmer JM, McKenney S, et al. Modulation of gastrointestinal function by MuDelta, a mixed µ opioid receptor agonist/µ opioid receptor antagonist. Br J Pharmacol. 2012;167(5):1111–25.
6. Sobolewska-Włodarczyk A, Włodarczyk M, Storr M, et al. Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome. Ther Clin Risk Manag. 2016;12:771–5.
7. Fujita W, Gomes I, Dove LS, et al. Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers. Biochem Pharmacol. 2014;92(3):448–56.
8. Levy-Cooperman N, McIntyre G, Bonifacio L, et al. Abuse potential and pharmacodynamic characteristics of oral and intranasal eluxadoline, a mixed µ- and κ-opioid receptor agonist and δ-opioid receptor antagonist. J Pharmacol Exp Ther. 2016;359(3):471–81.
9. Davenport JM, Hunt T, Dove LS. Eluxadoline has no effect on cardiac repolarization [abstract no. PII-017]. Clin Pharmacol Ther. 2016;99(Suppl 1):S79.
10. Davenport JM, Marbury T, Berg J, et al. Effect of hepatic impairment on eluxadoline pharmacokinetics [abstract no. PI-023]. Clin Pharmacol Ther. 2016;99(Suppl 1):S37.
11. Davenport JM, Covington P, Bonifacio L, et al. Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline. J Clin Pharmacol. 2015;55(5):534–42.
12. Dove LS, Lembo A, Randall CW, et al. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology. 2013;145(2):329–38.
13. Lembo AJ, Lacy BE, Zuckerman MJ, et al. Eluxadoline for irritable bowel syndrome with diarrhea. N Engl J Med. 2016;374(3):242–53.
14. Lacy B, Chey W, Lembo A, et al. Eluxadoline demonstrates efficacy for the treatment of irritable bowel syndrome (IBS) with diarrhoea (IBS-D) among multiple clinically relevant patient subgroups [abstract no. OC-070]. Gut. 2016;65(Suppl 1):A42–3.
15. Lacy BE, Chey WD, Cash BD, et al. Eluxadoline efficacy in IBS-D patients who report prior loperamide use. Am J Gastroenterol. 2017. doi:10.1038/ajg.2017.72.
16. Chey WD, Dove LS, Andrae DA, et al. Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two phase 3 studies. Aliment Pharmacol Ther. 2017;45(10):1319–28.
17. Cash BD, Lacy BE, Schoenfeld PS, et al. Safety of eluxadoline in patients with irritable bowel syndrome with diarrhea. Am J Gastroenterol. 2017;112(2):365–74.
18. Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62(1):102–11.
19. Fant RV, Henningfield JE, Cash BD, et al. Eluxadoline demonstrates a lack of abuse potential in phase 2 and 3 studies of patients with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol. 2017. doi:10.1016/j.cgh.2017.01.026.
20. Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109(Suppl 1):S2–26.
21. Lacy BE, Moreau JC. Diarrhea-predominant irritable bowel syndrome: diagnosis, etiology, and new treatment considerations. J Am Acad Nurse Pract. 2016;28(7):393–404.
22. Quigley EMM, Fried M, Gwee K-A, et al. World Gastroenterology Organisation global guidelines irritable bowel syndrome: a global perspective update September 2015. J Clin Gastroenterol. 2016;50(9):704–13.
23. National Institute for Health Care and Excellence. Irritable bowel syndrome in adults: diagnosis and management. Clinical guideline. 2015. https://www.nice.org.uk/. Accessed 23 Mar 2017.
24. Cash BD. Eluxadoline: a promising therapy that raises many questions. Transl Gastroenterol Hepatol. 2016;1:76.
25. Buono JL, Carson RT, Flores NM. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. Health Qual Life Outcomes. 2017;15(1):35.
26. Buono JL, Mathur K, Averitt AJ, et al. Economic burden of inadequate symptom control among US commercially insured patients with irritable bowel syndrome with diarrhea. J Med Econ. 2017;20(4):353–62.
27. McNeil Products Ltd. Imodium original 2 mg capsules: summary of product characteristics. 2016. http://www.medicines.org.uk/emc/medicine/23101. Accessed 23 Mar 2017.
28. Afghani E, Lo SK, Covington PS, et al. Sphincter of Oddi function and risk factors for dysfunction. Front Nutr. 2017. doi:10.3389/fnut.2017.00001.